Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $16.00.

COYA has been the topic of a number of recent research reports. BTIG Research raised their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, January 8th. D. Boral Capital restated a “buy” rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Monday, January 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Monday, November 24th.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in shares of Coya Therapeutics during the 3rd quarter worth approximately $28,000. Lantern Wealth Advisors LLC bought a new position in Coya Therapeutics in the 3rd quarter valued at about $66,000. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the second quarter valued at approximately $119,000. Prosperity Wealth Management Inc. raised its holdings in shares of Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Stock Performance

Shares of COYA opened at $4.75 on Thursday. Coya Therapeutics has a 1 year low of $4.55 and a 1 year high of $8.29. The company has a market cap of $99.37 million, a price-to-earnings ratio of -4.28 and a beta of 0.25. The firm has a fifty day moving average of $5.79 and a 200-day moving average of $6.03.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.